We bring scientific breakthroughs closer to patients and dermatologists, developing innovative treatments and solutions that address real patient needs.
I am a
I am looking for...
We contribute to improving the lives of millions of people worldwide across more than 100 countries. We are fully dedicated to medical dermatology with a focus on science and innovation.
Stories from people living with skin conditions
1/5
Ivet
Psoriasis
''My mum, who has psoriasis, has helped me a lot.''
Fede
Actinic keratosis
"When I discovered that AK was caused by solar damage, I was scared."
Mireia
Atopic dermatitis
"Atopic dermatitis can really affect your mental health."
We put patients and their families at the heart of every decision, guided by our purpose to transform their lives and help them achieve healthier futures.
With decades of investment in R&D, we advance skin biology and innovate alongside experts worldwide to deliver real impact for patients and dermatologists.
As a family-owned company, we act with integrity and transparency, and we are committed to sustainability through our Act4Impact 2030 strategy and guided by a long-term vision that creates value for people and society.
Latest updates on Almirall’s research, partnerships, and initiatives, offering patients and healthcare professionals clear insights into innovations shaping the future of dermatology.
1/5
Today, on World Psoriasis Day, we’re looking beyond the visible and raising awareness of the impact psoriasis can have beyond the skin. In a digital world increasingly shaped by filters and edited images, the realities of living with a visible skin condition can easily go unseen.
In the first nine months of 2026, we continued to deliver solid results, driven by strong commercial and operational execution and the continued growth of our European Dermatology business. Total Net Sales increased by 8.3% year-on-year to €889.2 million, while EBITDA grew by 22.7% to €221.7 million, reaching a 24.9% margin.
In the first nine months of 2026, we continued to deliver solid results, driven by strong commercial and operational execution and the continued growth of our European Dermatology business. Total Net Sales increased by 8.3% year-on-year to €889.2 million, while EBITDA grew by 22.7% to €221.7 million, reaching a 24.9% margin.
Today, on World Psoriasis Day, we’re looking beyond the visible and raising awareness of the impact psoriasis can have beyond the skin. In a digital world increasingly shaped by filters and edited images, the realities of living with a visible skin condition can easily go unseen.
At Almirall, we are dedicated to medical dermatology. Through our in-house R&D capabilities and collaborations with leading strategic partners, we work to advance the scientific understanding of skin diseases and develop innovative solutions that address real patient needs.
Last week in Vienna, we had the opportunity to connect with healthcare professionals, researchers and partners from across the global dermatology community. As Gold Sponsors, we were proud to contribute to the exchange of scientific knowledge to help advance the understanding of skin diseases.
Next week, we will be in Vienna for EADV 2026 as Gold Sponsors, one of the leading international congresses in dermatology, bringing together healthcare professionals, researchers, industry experts, and partners from around the world to share knowledge and explore the latest advances in skin health
